Oregon Public Employees Retirement Fund’s Coherus Oncology CHRS Stock Holding History

Oregon Public Employees Retirement Fund’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,810	Closed	-$88.9K	–	1675
2023 Q2	$88.9K	Sell	20,810 -500	-2%	-$2.95K	﹤0.01%	1680
2023 Q1	$146K	Sell	21,310 -60	-0.3%	-$466	﹤0.01%	1634
2022 Q4	$169K	Buy	21,370 +296	+1%	+$2.28K	﹤0.01%	1611
2022 Q3	$203K	Hold	21,074	–	–	﹤0.01%	1553
2022 Q2	$153K	Sell	21,074 -39,863	-65%	-$347K	﹤0.01%	1468
2022 Q1	$787K	Sell	60,937 -500	-0.8%	-$6.36K	0.01%	1198
2021 Q4	$981K	Sell	61,437 -69,924	-53%	-$1.22M	0.01%	1026
2021 Q3	$2.11M	Buy	131,361 +883	+0.7%	+$12.9K	0.02%	584
2021 Q2	$1.8M	Hold	130,478	–	–	0.02%	670
2021 Q1	$1.91M	Buy	130,478 +990	+0.8%	+$16.8K	0.02%	610
2020 Q4	$2.25M	Sell	129,488 -396	-0.3%	-$7.05K	0.03%	489
2020 Q3	$2.38M	Buy	129,884 +105,584	+435%	+$1.96M	0.04%	410
2020 Q2	$434K	Buy	+24,300	New	+$411K	0.01%	1160

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Oregon Public Employees Retirement Fund's CHRS Position: Q3 2023 in Review

Oregon Public Employees Retirement Fund sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 20,810 shares — an estimated $88.9K sold.

Oregon Public Employees Retirement Fund first reported a position in CHRS in Q2 2020 and held it in 13 quarters. The position peaked at $2.38M in Q3 2020. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Oregon Public Employees Retirement Fund reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
Oregon Public Employees Retirement Fund sold 20,810 Coherus Oncology shares in Q3 2023, an estimated $88.9K.
Oregon Public Employees Retirement Fund first reported a position in Coherus Oncology in Q2 2020 and held it in 13 quarters.
Oregon Public Employees Retirement Fund's Coherus Oncology position peaked at $2.38M in Q3 2020.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Oregon Public Employees Retirement Fund's 13F filing for Q3 2023, filed 27 Oct 2023.